RxDoctor Payments Data

Munsoor Lateef, MD

Nephrology · Burlington, NCNPI 1073716742

Payments from drug & device makers

$12,298in general payments, 2019–2025

Across 224 payments — averaging $54.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$8K
  • AstraZeneca$949
  • Amgen$826
  • Otsuka America Pharmaceutical, Inc.$506
  • Aurinia Pharma U.S., Inc.$415
  • Calliditas Therapeutics US Inc.$295
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$6,78155%
  • Travel & lodging$1371%
  • Food & beverage$5,14642%
  • Education$2332%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,298 in reported general payments places this provider in the 80th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$216,131
Medicare patients
305
Services billed
1,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan14$282,102
FarxigaDapagliflozin Propanediol269$215,845
JardianceEmpagliflozin126$72,361
VeltassaPatiromer Calcium Sorbitex23$28,467
Sevelamer Carbonate41$6,209
Calcitriol350$6,044
Calcium Acetate43$5,537
Mycophenolic AcidMycophenolate Sodium11$3,565
Losartan Potassium323$2,392
Telmisartan15$1,564
Febuxostat12$1,154
Enalapril Maleate23$834
Torsemide24$614
Midodrine Hcl23$607
Amlodipine Besylate165$575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$506$282,10214 claims
AstraZenecaFarxiga$949$215,845269 claims
Boehringer IngelheimJardiance$105$72,361126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →